International Journal of Diabetes Mellitus
Volume 2, Issue 1 , Pages 43-46 , April 2010

The challenge of undiagnosed pre-diabetes, diabetes and associated cardiovascular disease

  • Ved V. Gossain

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Division of Endocrinology, Department of Medicine, B323, Clinical Center, Michigan State University, East Lansing, MI 48824, USA. Tel.: +1 517 353 3730; fax: +1 517 432 1326.
    • ,
  • Saleh Aldasouqi

      Affiliations

    • Present address: Cape Diabetes and Endocrinology and Cape Thyroid Center, Saint Francis Diabetes Center, 17 Doctors Park, Cape Girardeau, MO 63703, USA.

Received 7 August 2009 ,Accepted 24 October 2009.

References 

  1. The American Diabetes Association. <http://www.diabetes.org/diabetes-statistics/prevalence.jsp> [accessed 12.08.08].
  2. Cowie CC, Rust KF, Ford ES, Eberthardt MS, Byrd-Holt DD, Li C, et al. Full accounting of diabetes and pre-diabetes in the US population in 1988–1994 and 2005–2006. Diab Care. 2009;32(2):287–294
  3. Pierce MB, Zaniotto P, Steel N, Mindell J. Undiagnosed diabetes – data from English longitudinal study of ageing. Diab Med. 2009;26:625–679
  4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diab Care 2004;27(5):1047–53.
  5. IDF – Diabetes Atlas: Prevalence – http://www.eatlas.idf.org/indexcc67.html; 2009.
  6. Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002;19:708–723
  7. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance. Systematic review and meta-analysis. BMJ. 2007;334(7588):299–307
  8. Zhiheng H, King GL. Microvascular complications of diabetes. Endocrinol Metab Clin North Am. 2004;33:215–238
  9. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59(1):8–13
  10. Harris MI, Entmacher PS. Mortality from diabetes. In:  Harris MI,  Hamman R editor. Diabetes in America. Washington, DC: US Government Printing Office; 1985;p. 1–48[Publication #85-1468]
  11. Aldasouqi SA, Gossain VV, Little RR. Undiagnosed diabetes equals undiagnosed CVD: a call for more effective diabetes screening. Rev Endocrinol. 2009;3:21–23
  12. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039–57.
  13. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab Care 1997;20(7):1183–97.
  14. The expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diab Care 2003;26(11):3160–67.
  15. ACE/AACE consensus statement. Diagnosis and management of pre-diabetes in the continuum of hyperglycemia. Endo Pract 2008;14:933–46.
  16. Alberti KGMM, Zimmet P, Shaw J. International diabetes federation: a consensus on type 2 diabetes prevention. Diab Med. 2007;24:451–463
  17. Shaw JE, Zimmet PZ, De Courten M, Dowse GK, Chitson P, Gareeboo H, et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?. Diab Care. 1999;22:399–402
  18. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diab Care. 1999;22:920–924
  19. Wong TY, Liew G, Tapp RJ, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population based cross sectional studies. Lancet. 2008;371:736–743[erratum in Lancet 2008;371:1838]
  20. Haffner S, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med. 2003;115(Suppl. 8ª):6s–11S
  21. Levitzky YS, Pencina MJ, D’Agostino RB, Meigs JM, Vasan RS, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham heart study. J Am Coll Cardiol. 2008;22:264–270
  22. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet. 1980;1:1373–1376
  23. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago heart association detection project in industry study. Diab Care. 1997;20:163–169
  24. DECODE study group. The European diabetes epidemiology group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Int Med 2001;161:397–404.
  25. Nathan DM. Long-term complications of diabetes mellitus. NEJM. 1993;328:1676–1685
  26. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035–2038
  27. Khaw KT, Warcham N, Bingham S, Luben R, Welch A, Day N. Association of HbA1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Int Med. 2004;141:413–420
  28. Danaei G, Lawes CMM, Vander Hoorn S, Murray CJL, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet. 2006;368:1651–1659
  29. Saydah S, Imperatore G, Tao M, Gregg E. GHb level and subsequent mortality among adults in the US. Diab Care. 2009;32:1440–1446
  30. Dale AC, Midthjell K, Nilsen TI, Wiseth R, Vatten LJ. Glycaemic control in newly diagnosed diabetes patients and mortality from ischaemic heart disease: 20-year follow-up of the HUNT study in Norway. Eur Heart J. 2009;30:1372–1377
  31. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM 1993;329:977–86.
  32. UK prospective diabetes study [UKPDS] group. Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes [UKPDS 33]. Lancet 1998;352:837–53.
  33. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  34. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes. NEJM. 2008;359:1577–1589
  35. American diabetes association. Clinical practice recommendations 2009. Diab Care 2009;32(Suppl. 1):s1–94.
  36. Nathan DM. Glycemic management of type 2 diabetes. Arch Intern Med. 2008;168:2064–2066
  37. The action to control cardiovascular risk in diabetes study group. Effects of intensive glucose lowering in type 2 diabetes. NEJM 2008;358:2545–59.
  38. The ADVANCE collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. NEJM 2008;358:2560–72.
  39. Goede P, Lund-Andersen H, Parving HH, Pederson O. Effect of a multifactorial intervention on mortality in type 2 diabetes. New Eng J Med. 2008;358:580–591
  40. US preventive services task force. Screening for type 2 diabetes mellitus in adults: US preventive services task force recommendation statement. Annals of Int Med 2008;148:846–55.
  41. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modeling. Health Technol Assess. 2007;11:1–125
  42. Sheehy AM, Coursin DB, Gabbay RA. Back to Wilson and Jungner: 10 good reasons to screen for type 2 diabetes mellitus. Mayo Clin Proc. 2009;84:38–42
  43. Lawler FH. Reasons to exercise caution when considering a screening program for type 2 diabetes mellitus. Mayo Clin Proc. 2009;84:34–36
  44. Aldasouqi SA, Gossain VV. Revisiting screening for type 2 diabetes mellitus: to screen or not to screen, that is the question. Mayo Clin Proc. 2009;
  45. Perry RC, Shankar RR, Finberg N, McGill J, Baron AD. HbA1c measurements improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the early diabetes intervention program [EDIP]. Diab Care. 2001;24:465–471
  46. Bennett CM, Guo M, Dharmage SC. HbA1c as a screening tool for detection of type 2 diabetes: a systematic review. Diab Med. 2007;24:333–343
  47. Aldasouqi SA, Gossain VV. HbA1c: past, present and future. Ann Saudi Med. 2008;28:411–419
  48. Aldasouqi SA, Solomon D, Bokhari SA, Khan PM, Muneera S, Gossain VV. Glycohemoglobin A1c: A promising screening tool in gestational diabetes mellitus. Int J Diab Dev Ctries. 2008;28(4):121–124
  49. McCane DR, Hanson RL, Charles MA, Jacobsson LTH, Pettit D, Bennett PH, et al. Comparison of tests for gyrated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994;308:1323–1328
  50. Saudek CD, Herman WH, Saeks DB, Bergenstal RM, Edelman D, Davidson MB. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab. 2008;93:2447–2453
  51. American diabetic association. Professional section quarterly. Winter 2009. p. 1.
  52. Fachnie JD, Whitehouse FW, McGrath Z. Vomiting during OGTT in third trimester of pregnancy. Diab Care. 1988;11:818
  53. Artal R, Mosley GM, Doney FJ. Glycohemoglobin as a screening test for gestational diabetes. Am J Obstet Gynecol. 1984;148:412–414
  54. Morris MA, Grandis AS, Litton J. Glycosylated hemoglobin a sensitive indicator of gestational diabetes. Obstet Gynecol. 1986;68:357–361
  55. Shah BD, Cohen AW, May C, Gabbe SG. Comparison of glycohemoglobin determination and one hour glucose screen in identification of gestational diabetes. Am J Obstet Gynecol. 1982;144:774–777
  56. McFarland KF, Murtiashaw M, Baynes JW. Clinical value of glycosylated serum proteins and glycosylated hemoglobin levels in the diagnoses of gestational diabetes mellitus. Obstet Gynecol. 1984;64:516–518
  57. Cocilovo G, Guerra S, Coka F, Tomasi F. Glycosylated hemoglobin [HbA1] assay as a test for detection and surveillance of gestational diabetes. A reappraisal. Diab Metab. 1987;13:426–430
  58. Agarwal MM, Hughes PF, Punnose J, Ezimokhai M, Thomas L. Gestational diabetes screening of a multiethnic, high-risk population using glycated proteins. Diab Res Clin Pract. 2001;51:67–73
  59. Agarwal MM, Dhatt G, Punnose J, Koster G. Gestational diabetes: a reappraisal of HbA1c as a screening test. Acta Obstet Gynecol Scan. 2005;84:1159–1163
  60. Simmons D, Rowan J, Reid R, Campbell N. On behalf of national GDM working party. Screening, diagnosis and services for women with gestational diabetes mellitus [GDM] in New Zealand: a technical report from the national GDM technical working party. New Zealand Med J. 2008;121:74–85

PII: S1877-5934(09)00056-3

doi: 10.1016/j.ijdm.2009.10.004

International Journal of Diabetes Mellitus
Volume 2, Issue 1 , Pages 43-46 , April 2010

Article Tools